Patents Assigned to Merck
  • Electrooptical liquid crystal system
    Patent number: 6565769
    Abstract: To improve switching times, especially at low temperatures, one or more reactive liquid crystalline compounds is added to a liquid crystal mixture used in an electrooptical system. The electrooptical system comprises a PDLC film comprising a liquid crystal mixture forming micro- droplets in an optically isotropic, transparent polymer matrix between 2 electrode layers, one of the refractive indices of the liquid crystal mixture is matched to the refractive index of the polymer matrix, the PDLC film exhibits an electrically switching transparency essentially independent of the polarization of the incident light, the precursor of the PDLC film comprises one or more monomers, oligomers and/or prepolymers and a photoinitiator, and is cured photoradically, the liquid crystal mixture comprises one or more compounds of the formula I  wherein R, A1, A2, Z1, Z2, X1, X2, Q, Y and n are as defined herein.
    Type: Grant
    Filed: December 29, 2000
    Date of Patent: May 20, 2003
    Assignee: Merck Patent GmbH
    Inventors: David Coates, Owain Llyr Parri, Simon Greenfield, Martin David Tillin, Mark John Goulding, Patrick Nolan
  • Cyclopeptide derivatives
    Patent number: 6566491
    Abstract: The invention relates to compounds of the formula (I) R1—Q1—X—Q2—R2, in which: Q1, Q2, each independent of one another, are missing or are —NH—(CH2)n—CO—; R1, R2, each independent of one another, are missing or are cyclo-(Arg-Gly-Asp-Z), wherein Z is missing in side chain of Q1 or Q2 of if Q1 and/or Q2 missing, is bound to X, at least one of the groups R1 or R2 always having to be included; X is —CO—R18—CO—, and if R1—Q1— or R2—Q2— are missing is R10, R13, Het-CO or a flourescent pigment residue linked through a —CONH—, —COO—, NH—C(═S)—N—, —NH—C(═O)—NH—, —SO2 NH—or —NHCO— bond; and Z, R10, R13, R16, R18, Het and n have the meaning given in claim 1. The invention also relates to the salts of said compounds.
    Type: Grant
    Filed: August 18, 1998
    Date of Patent: May 20, 2003
    Assignee: Merck Patent Gesellschaft
    Inventors: Alfred Jonczyk, Simon Lawrence Goodman, Beate Diefenbach, Arne Sutter, Horst Kessler
  • Liquid-crystalline medium
    Patent number: 6565933
    Abstract: Liquid-crystalline mediums based on a mixture of polar compounds having positive dielectric anisotropy, characterized in that they comprise one or more compounds of the general formula I in which R, A1, Z1, Y and L are as defined herein, are suitable for use in MLC, TN and STN displays.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: May 20, 2003
    Assignee: Merck Patent GmbH
    Inventors: Kazuaki Tarumi, Brigitte Schuler, Eike Poetsch, Volker Reiffenrath, Yukiomi Tanaka
  • Adenovirus vectors generated from helper viruses and helper-dependent vectors
    Patent number: 6566128
    Abstract: The present invention provides an improved helper-dependent vector system for production of high capacity adenoviral cloning vectors. The invention makes use of the DNA size packaging constraints imposed on a pIX-defective Ad virion that prevent such virions from packaging DNA larger than approximately 35 kb. This constraint can be used to develop helper viruses that do not package their DNA. In one embodiment, the invention combines this methodology with the Cre-loxP helper-dependent system to decrease the quantity of contaminating helper virus in vector preparations. In another embodiment the invention is used for vector growth.
    Type: Grant
    Filed: November 15, 1999
    Date of Patent: May 20, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Frank L. Graham, Robin Parks, Liane Chen
  • Inhibitors of prenyl-protein transferase
    Patent number: 6566385
    Abstract: The present invention is directed to peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.
    Type: Grant
    Filed: January 9, 2001
    Date of Patent: May 20, 2003
    Assignee: Merck & Co., Inc.
    Inventors: S. Jane deSolms, Gerald E. Stokker, Anthony W. Shaw
  • Process for preparing 1-(6-methylpyridin-3-yl)-2-[4-methylsulphonyl)-phenyl]ethanone
    Patent number: 6566527
    Abstract: A five-step process for preparing 1-(6-methylpyridin-3-yl)-2-[4-methylsulfonyl)phenyl]ethanone of formula (I): The process involves the following steps: (a) 4-(methylthio)benzyl alcohol is converted into 4-(methylthio)benzyl chloride; (b) 4-(methylthio)benzyl chloride is converted with an alkali metal cyanide into 4-(methylthio)phenylacetonitrile; (c) 4-(methylthio)phenylacetonitrile is condensed with a 6-methyinicotinic ester to give 3-[2-(2-(methylthio)phenyl)-2-cyanoacetyl](6-methyl)pyridine; (d) 3-[2-(4-(methylthio)phenyl-2-cyanoacetyl](6-methyl)pyridine is hydrolyzed and decarboxylated under acidic conditions to give 3-[2-(4-(methylthio)-phenyl)acetyl](6-methyl)pyridine is hydrolyzed and decarboxylated under acidic conditions to give 3-[2-(4-(methylthio)phenyl)acetyl(6-methyl)pyridine; and (e) 3-[2(4-(methylthio)phenyl)acetyl](6-methyl)pyridine is oxidized to give the end product.
    Type: Grant
    Filed: March 14, 2002
    Date of Patent: May 20, 2003
    Assignees: Merck & Co., Inc., Lonza AG
    Inventors: Yves Bessard, James Edward Leresche
  • Dispenser for liquids
    Patent number: 6564974
    Abstract: A dispensing appliance for liquids consists of at least one cabinet-like supply module (1) and of a cabinet-like dispensing module (2) connected to the latter. A pull-out trolley (3) can be moved out of the front side of the supply module (1) and serves for receiving a supply container (8) which can be inserted through one of the two open side faces (6). The dispensing module has a dispensing space (17) accessible from the front side. The supply module (1) has a square plan contour with an edge length (a) which is equal to the depth (t) of the dispensing module (2) designed with a rectangular plan contour. The dispensing module (2) can be connected selectively to each of the three side faces (11, 18, 19) of the supply module (1).
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: May 20, 2003
    Assignee: Merck Patentgesellschaft
    Inventor: Peter Manzke
  • Polynucleotide encoding estrogen receptor
    Patent number: 6562592
    Abstract: This invention relates to a novel estrogen receptor and to the polynucleotide sequences encoding this receptor. This invention also relates to methods for identifying ligands which bind to this receptor, to the ligands so identified, and to pharmaceutical compositions comprising such ligands. This invention also relates to pharmaceutical compositions useful for treating or preventing estrogen receptor mediated diseases or conditions, such as abnormal bone resorption, cardiovascular diseases, cancer, or central nervous system disorders.
    Type: Grant
    Filed: April 26, 2000
    Date of Patent: May 13, 2003
    Assignee: Merck & Co., Inc.
    Inventor: Hilary Wilkinson
  • Process for producing inorganic porous material in a capillary
    Patent number: 6562744
    Abstract: Inorganic porous materials contained in a confined space with at least one dimension of less than 1 mm, which are in liquid tight contact with the walls of said confined space. Preferred as the confined space are capillaries. Articles contained such materials and methods for making them in the confined space are described.
    Type: Grant
    Filed: July 21, 2000
    Date of Patent: May 13, 2003
    Assignee: Merck Patent GmbH
    Inventors: Kazuki Nakanishi, Naohiro Soga, Tokiyo Minakuchi
  • Matrix liquid crystal display
    Patent number: 6562419
    Abstract: The invention relates to a matrix liquid crystal display containing integrated non-linear elements and a liquid crystal mixture which has a particularly high resistivity.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: May 13, 2003
    Assignee: MERCK Patent Gesellschaft mit beschrankter Haftung
    Inventors: Georg Weber, Ludwig Pohl, Reinhard Hittich, Herbert Plach, Bernhard Scheuble, Takamasa Oyama, Bernhard Rieger, Hans Adolf Kurmeier, Ekkehard Bartmann
  • Inhibitors of prenyl-protein transferase
    Patent number: 6562823
    Abstract: The present invention is directed to peptidomimetic piperazine-containing macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: May 13, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Christopher J. Dinsmore, Jeffrey M. Bergman, Samuel L. Graham, Diem N. Nguyen, Gerald E. Stokker, Theresa M. Williams, C. Blair Zartman
  • Polymerizable liquid crystal material
    Publication number: 20030085377
    Abstract: The invention relates to a polymerizable liquid crystal material containing at least one polymerizable surface-active compound, its use for the preparation of anisotropic polymer films, and the use of the liquid crystal material and the polymer films in optical and electrooptical devices, and for decorative and security applications.
    Type: Application
    Filed: May 1, 2002
    Publication date: May 8, 2003
    Applicant: MERCK PAPTENTGESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Christopher J. Dunn, Simon Greenfield, Richard Harding, Ian Victor Edward Hassall, Alison Linda May, Julian Frederick Samuel Vaughan-Spickers
  • Mono-, oligo- and polymers of benzo[b]thiophene and 2,2'-bisbenzo[b]thiophene and their use as charge transport materials
    Publication number: 20030085381
    Abstract: Conjugated mono-, oligo- and polymers of benzo[b]thiophene and bisbenzo[b]thiophene are useful as semiconductors or charge transport materials in optical, electrooptical or electronic devices including field effect transistors, electroluminescent, photovoltaic and sensor devices.
    Type: Application
    Filed: September 27, 2002
    Publication date: May 8, 2003
    Applicant: Merck Patent GmbH
    Inventors: Christopher Worrall, Martin Heeney, Steven Tierney, Louise Diane Farrand, Mark Giles, Marcus Thompson, Maxim Shkunov, David Sparrowe, Iain McCulloch
  • N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors
    Patent number: 6559174
    Abstract: Compounds of Formula I are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: May 6, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Linus S. Lin, Shrenik K. Shah, Linda L. Chang, William K. Hagmann, Richard A. Mumford
  • Preparation and isolation of indolocarbazole glycosides
    Patent number: 6559299
    Abstract: The present invention relates to a novel process to make indolocarbazole glycosides in high purity which inhibit the growth of tumor cells and are therefore useful in the treatment of cancer in mammals, and the like.
    Type: Grant
    Filed: March 21, 2002
    Date of Patent: May 6, 2003
    Assignees: Merck & Co., Inc., Banyu Pharmaceutical Co., Ltd.
    Inventors: Steven Weissman, David Tschaen, Asayuki Kamatani, Shouichi Hiraga, Masashi Kawasaki, Takehiko Iida
  • Phenylsulphonyl derivatives as 5-HT receptor ligands
    Patent number: 6559166
    Abstract: A class of phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached to an N-arylalkyl-substituted azetidine, pyrrolidine or piperidine ring are selective antagonists of the human 5-HT2A receptor and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of adverse conditions of the central nervous system, including schizophrenia and depression.
    Type: Grant
    Filed: September 27, 2001
    Date of Patent: May 6, 2003
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Peter Blurton, Frank Burkamp, Susan Koon-Fung Cheng, Stephen Robert Fletcher, Angus Murray MacLeod, Daniel Spinks, Monique Bodil Van Niel
  • Method of adsorbing metals and organic compounds from vaporous streams
    Patent number: 6558642
    Abstract: A method and adsorption powder useful for the removal of mercury and other metals, as well as furans, dioxins and other organic compounds from high temperature and high moisture gaseous streams. The method utilizes an adsorption powder characterized as containing a carbon-based powder and an effective amount of cupric chloride suitable to remove metals and organic compounds. The powder may contain calcium hydroxide, sulfur, potassium permanganate, potassium iodide, and combinations thereof.
    Type: Grant
    Filed: March 29, 2001
    Date of Patent: May 6, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Youssef El-Shoubary, Rudy Maes
  • Nitromethyl ketone compounds having aldose reduction inhibiting properties and methods for their use
    Patent number: 6559185
    Abstract: The present invention relates to the compounds of formula: in which R1, R2, R3, E, A, X, Z, p and n are as defined herein. These compounds are aldose reductase inhibitors.
    Type: Grant
    Filed: November 12, 1999
    Date of Patent: May 6, 2003
    Assignee: Merck Patent GmbH
    Inventors: Claude Lardy, Jaques Barbanton, Herve Dumas, Francois Collonges, Philippe Durbin
  • Bicyclic amino acids
    Patent number: 6559144
    Abstract: Compounds of the formula I in which X, Y, Z, R1, R2, R3, R4, R5, R7, R8, R11, m and n have the meanings stated in claim 1, and their physiologically acceptable salts can be used as integrin inhibitors, in particular for the prophylaxis and treatment of circulatory disorders, for thrombosis, myocardial infarct, coronary heart disease, arteriosclerosis, osteoporosis, for pathological processes maintained or propagated by angiogenesis, and in tumour therapy.
    Type: Grant
    Filed: April 26, 2001
    Date of Patent: May 6, 2003
    Assignee: Merck Patent Gesellschaft Mit
    Inventors: Beate Diefenbach, Simon L. Goodman, Joachim März, Peter Raddatz, Friedrich Rippmann, Matthias Wiesner
  • Reactive thienothiophenes
    Publication number: 20030080322
    Abstract: The invention relates to reactive thienothiophenes, their use as semiconductors or charge transport materials, in optical, electrooptical or electronic devices like for example organic field effect transistors (FET or OFET) for thin film transistor liquid crystal displays and integrated circuit devices such as RFID tags, electroluminescent devices in flat panel displays, and in photovoltaic and sensor devices, and to a field effect transistor, light emitting device or ID tag comprising the reactive thienothiophenes.
    Type: Application
    Filed: July 9, 2002
    Publication date: May 1, 2003
    Applicant: Merck Patent GmbH
    Inventors: Louise Farrand, Marcus Thompson, Mark Giles, Mark Goulding, Martin Heeney, Steven Tierney, Maxim Shkunov, David Sparrowe, Iain McCulloch